Physician

Hematology

Dr. Martin J. Korbling, MD

Martin Korbling works in the field of Hematology. Martin Korbling is a published doctor and has 28 publications published. The lastest was: 'Comparison of Survival in Patients with T Cell Lymphoma after Autologous and Allogeneic Stem Cell Transplantation as a Frontline Strategy or in Relapsed Disease.' He accepts Medicare payments and is registered with Medicare.gov.

Publications

Comparison of Survival in Patients with T Cell Lymphoma after Autologous and Allogeneic Stem Cell Transplantation as a Frontline Strategy or in Relapsed Disease.
BFR (bendamustine, fludarabine, and rituximab) allogeneic conditioning for chronic lymphocytic Leukemia/lymphoma: reduced myelosuppression and GVHD.
Cytarabine, Ki-67, and SOX11 in patients with mantle Cell lymphoma receiving rituximab-containing autologous stem Cell transplantation during first remission.
Cord-blood engraftment with ex vivo mesenchymal-Cell coculture.
Improved Early Outcomes Using a T Cell Replete Graft Compared with T Cell Depleted Haploidentical Hematopoietic Stem Cell Transplant.
Nonmyeloablative allogeneic transplantation with or without 90yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular Lymphoma: 12-year results.
Donor-specific anti-HLA antibodies and graft failure in matched unrelated donor hematopoietic stem Cell transplantation.
High risk of graft failure in patients with anti-HLA antibodies undergoing haploidentical stem-Cell transplantation.
Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma.
Disease staging with positron emission tomography or gallium scanning and use of rituximab predict outcome for patients with diffuse large B-Cell lymphoma treated with...
Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in...
Eight-year experience with allogeneic stem Cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide...
Graft-versus-leukaemia effect after non-myeloablative haematopoietic transplantation can overcome the unfavourable expression of ZAP-70 in refractory Chronic lymphocyt...
Transplant-associated microangiopathy in patients receiving tacrolimus following allogeneic stem Cell transplantation: risk factors and response to treatment.
The effect of low dose gamma irradiation on the differentiation and maturation of monocyte derived dendritic Cells.
Circulating endothelial progenitor Cells and coronary collaterals in patients with non-ST segment elevation myocardial infarction.
Concurrent administration of high-dose rituximab before and after autologous stem-Cell transplantation for relapsed aggressive B-Cell non-Hodgkin's lymphomas.
Designing an ethical policy for bone marrow donation by minors and others lacking capacity.
Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cel...
Engraftment of Acute myeloid leukemia in NOD/SCID mice is independent of CXCR4 and predicts poor patient survival.
Nonablative allogeneic stem cell transplantation for chronic lymphocytic Leukemia: impact of rituximab on immunomodulation and survival.
Bone marrow purging studies in Acute myelogenous leukemia using the recombinant anti-CD33 immunotoxin HuM195/rGel.
Double-chimaerism after transplantation of two human leucocyte antigen mismatched, unrelated cord blood units.
Use of thrombopoietin in combination with chemotherapy and granulocyte colony-stimulating factor for peripheral blood progenitor Cell mobilization.
Marginal keratitis associated with administration of filgrastim and sargramostim in a healthy peripheral blood progenitor Cell donor.
Ex vivo expansion of apheresis-derived peripheral blood hematopoietic progenitors.
Leukapheresis reduces early mortality in patients with Acute myeloid leukemia with high white cell counts but does not improve long- term survival.

Procedures Preformed

HPC Transplantation (Stem Cell Transplant)
Plasmapheresis
Thoracentesis

Conditions Treated

Acute Leukemia
Adrenal Gland Cancer
Anal and Rectal Cancer
Anemia
View All

Doctors Specialties

Hematology
Medical Oncology
Oncology

Accepted Insurances

Choice Plus POS II
American Republic
Amerigroup (Wellpoint)
Blue Card PPO
Blue Choice
Cigna HMO
Cigna PPO
Great West Healthcare-Cigna PPO
LocalPlus
Open Access Plus
Commercial Insurance Company
First Health (Coventry Health Care) PPO
Choice Care PPO
Medicare MCR
MultiPlan PPO
PHCS Network PPO
POMCO Group
Choice Plus POS
Navigate HMO
Navigate POS
Options PPO
United Healthcare

Hospital

University of Texas M.D. Anderson Cancer Center

Helpful Reviews

Give Anonymous Review

Medicare Facts

National Provider Identifier [NPI]	1376641308
Last Name Of The Provider	KORBLING
First Name Of The Provider	MARTIN
View All

Similar Doctors

	Dr. Kelty R. Baker, MD This Doctor is OpenDoctor Recommended.
	Dr. Philip L. Cimo, MD This Doctor is OpenDoctor Recommended. This doctor has more publications
	Dr. Kathryn A. Gold, MD This Doctor is OpenDoctor Recommended.
	Dr. Francesco Turturro, MD This Doctor is OpenDoctor Recommended. This doctor has more publications
	Dr. Phuong Khanh H. Morrow, MD
	Dr. Maria A. Zarzour, MD This Doctor is OpenDoctor Recommended.
	Dr. Naval G. Daver, MD This Doctor is OpenDoctor Recommended. This doctor has more publications
	Dr. Julie R. Nangia, MD This Doctor is OpenDoctor Recommended.
	Dr. David J. Stewart, MD
	Dr. Nicholas Mitsiades, MD This Doctor is OpenDoctor Recommended. This doctor has more publications
	Dr. Bonnie S. Glisson, MD This Doctor is OpenDoctor Recommended. This doctor has more publications
	Dr. Labaron T. Washington, MD This Doctor is OpenDoctor Recommended.
	Dr. Joseph D. Khoury, MD This Doctor is OpenDoctor Recommended. This doctor has more publications
	Dr. Jorge E. Cortes-Franco, MD
	Dr. Bryan T. Hennessy, MD This Doctor is OpenDoctor Recommended. This doctor has more publications